Skip to content

Proposed pilot only: not funded and not running. Everything described here is planned for 2027–2028 in a simulated proposal. Learn more

Kushalam by MHEP

Potential impact

What AUD 407,525 could achieve in 24 months

Adjust the assumptions to see how uptake, follow-up and treatment translate into women screened, precancers treated and value for money.

Projected impact headline

At 70% uptake, Kushalam could give 4,760 women a valid HPV result, for about AUD 86 per valid result.

If the illustrative assumptions hold (7% HPV positivity, 10 CIN2+ per 1,000, 90% linkage and 90% treatment completion), about 39 precancers could be detected and treated.

ProjectedWomen with a valid result
4,760
of 6,800 eligible · about 238 per estate
ProjectedHPV-positive women linked to follow-up
300
of 333 HPV-positive · about 170 colposcopy referrals
ProjectedPrecancers (CIN2+) treated
39
of about 43 detected (48 expected among women screened)
ProjectedCost per valid result
AUD 86
≈ LKR 19,777 · total budget ÷ women with a result

Projected screen-and-treat cascade

Each step depends on the assumptions in the panel. These are scenario estimates, not results.

  1. Eligible women (line list)6,800
  2. Valid HPV result4,760

    70% of eligible

  3. HPV positive333

    7% of valid results

  4. Linked to triage or colposcopy300

    90% of HPV-positive

  5. CIN2+ detected43

    of 48 expected among women screened

  6. CIN2+ treated39

    91% of detected

Gated rollout, June 2027 to June 2028

Estates grow 4 → 8 → 12 → 20, each wave unlocked by a quality gate.

Closing the screening gap

Ever-screened rates (FHB & UNFPA, 2019) vs. Kushalam's projected coverage of its eligible women. The dashed line is WHO's 70% screening target.

Where the money goes

Year 1 AUD 190,507 · Year 2 AUD 217,018

  • Personnel and allowancesAUD 140,868
  • HPV tests, kits and equipmentAUD 118,702
  • Transport, vehicles, women’s travel and wagesAUD 85,453
  • Indirect costs (7%)AUD 26,660
  • Contingency (5%)AUD 18,136
  • Trainings and meetingsAUD 17,706

Targets vs. this scenario

  • Eligible women with a valid HPV resultBy Jul 202870%target ≥70%
  • Women needing assessment linked within 3 monthsBy Oct 202890%target ≥90%
  • Women with CIN2+ treatedBy Oct 202890%target ≥90%
  • Valid results acknowledged within 30 daysBy OngoingMeasuredtarget ≥95%
  • Process rated acceptable and privateBy Exit surveyMeasuredtarget ≥80%
  • No pay or attendance penalty reportedBy Exit surveyMeasuredtarget ≥95%

Safeguards for supporters: quality gates

Funds for each wave are released only after the previous gate is passed. A second miss ends expansion and unspent funds return to DFAT.

  1. Wave 1 · June 2027 → 4 estates

    First collection wave starts in 4 estates

  2. Gate 1 · August 2027 → 8 estates

    Consent ≥85% · Invalid samples ≤5% · Median turnaround ≤28 days · Booth throughput on plan · No confidentiality breach

  3. Gate 2 · November 2027 → 12 estates

    All Gate 1 measures · ≥95% of valid results acknowledged within 30 days · Colposcopy referrals within agreed capacity

  4. Gate 3 · February 2028 → 20 estates

    Waves 1–2 cover ≥60% of the line list · ≥80% of Wave 1 referrals linked within 3 months · Spending within ±10%

Gate 3 check in this scenario: waves 1–2 reach ~70% of their line list (needs ≥60%) · 170 est. colposcopy referrals across the pilot.

Prepared as a simulated funding proposal to DFAT for a university assignment; no funding application has been submitted. Dates, targets and figures are illustrative.

See the full case for supportAbout the proposal